Understanding how specific proteins regulate blood vessel growth
Reciprocal VEGFC/VEGFR3-CDH5 regulation of lymphatic and sinusoidal vascular growth
This study is looking at how two proteins, VEGFC and CDH5, help control the growth of special blood vessels, which could lead to better treatments for conditions like anemia and lymphedema by improving how these vessels regenerate.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11078732 on NIH RePORTER |
What this research studies
This research investigates the mechanisms by which certain proteins, specifically VEGFC and CDH5, control the growth of specialized blood vessels known as sinusoidal and lymphatic vessels. By studying these proteins in both living organisms and laboratory settings, the researchers aim to uncover how they interact and influence blood cell formation and vessel regeneration. The ultimate goal is to find ways to enhance the regeneration of these vessels, which could lead to better treatments for conditions like anemia and lymphedema.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients suffering from hematopoietic diseases or lymphedema who may benefit from enhanced vascular regeneration.
Not a fit: Patients with conditions unrelated to blood vessel growth or those who do not have hematopoietic or lymphatic disorders may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that improve blood vessel regeneration, benefiting patients with hematopoietic diseases and lymphedema.
How similar studies have performed: Previous research has shown promising results in understanding vascular growth mechanisms, suggesting that this approach may lead to significant advancements in treatment.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Kahn, Mark L — University of Pennsylvania
- Study coordinator: Kahn, Mark L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.